IPP Bureau
Krsnaa Diagnostics posts Q4 FY25 consolidated PAT at Rs. 20.67 Cr
By IPP Bureau - May 13, 2025
The company has posted net profit of Rs. 77.60 crores for the Financial Year ended March 31, 2025
Bliss GVS Pharma posts Q4 FY25 consolidated PAT at Rs. 15.53 Cr
By IPP Bureau - May 13, 2025
The company has posted net profit of Rs. 84.29 crores for the Financial Year ended March 31, 2025
Wanbury's Tanuku facility granted GMP certificate by ANVISA
By IPP Bureau - May 13, 2025
The inspection conducted from December 16, 2024 to December 20, 2024 by the Brazil Health Regulatory Agency (ANVISA)
Morepen Laboratories reports Q4 FY25 consolidated PAT at Rs. 20.31 Cr
By IPP Bureau - May 13, 2025
The company has posted net profit of Rs. 118.01 crores for the Financial Year ended March 31, 2025
Lupin launches Tolvaptan Tablets in the US with 180-day exclusivity
By IPP Bureau - May 13, 2025
Tolvaptan Tablets are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Morepen Board proposed dividend after 23 years
By IPP Bureau - May 13, 2025
Scores highest PAT of Rs. 118 crore in FY25
Kwality Pharmaceuticals concludes regulatory audit for Zimbabwe
By IPP Bureau - May 12, 2025
This marks yet another milestone in our series of successful audits over the past year
Poly Medicure posts Q4 FY25 consolidated profit at Rs. 91.83 Cr
By IPP Bureau - May 12, 2025
The company has posted net profit of Rs. 338.55 crores for the Financial Year ended March 31, 2025
Dabur India posts Q4 FY25 consolidated PAT at Rs. 320.13 Cr
By IPP Bureau - May 12, 2025
The company has posted net profit of Rs. 1,767.63 crores for the Financial Year ended March 31, 2025
Jagsonpal Pharmaceuticals posts Q4 FY25 PAT at Rs. 6.58 Cr
By IPP Bureau - May 12, 2025
The company has posted net profit of Rs. 55.36 crores for the Financial Year ended March 31, 2025
Indian School of Public Policy and Indegene announce strategic collaboration
By IPP Bureau - May 12, 2025
ISPP will analyze health systems across states, identifying scalable models and actionable insights to strengthen India's healthcare delivery
Aarti Drugs Ltd Q4 FY2025 consolidated PAT climbs to Rs. 62.86 Cr
By IPP Bureau - May 12, 2025
The company has posted net profit of Rs.168.16 crores for the Financial Year ended March 31, 2025
Zydus receives final approval from USFDA for Glatiramer Acetate Injection
By IPP Bureau - May 12, 2025
Glatiramer Acetate is the generic version of Copaxone 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
Agilent inaugurates India Solution Center to accelerate innovation
By IPP Bureau - May 09, 2025
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
Lupin launches Eslicarbazepine Acetate tablets in US
By IPP Bureau - May 08, 2025
Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity
